latest news, breaking news, business, finance analysis, comments and views from Nigeria :: Businessday

Clarion call to governments to invest in prevention programmes
New data published by the World Health Organisation in last week’s edition of ‘The Lancet’ touches on two leading causes of pneumonia, the world’s leading killer of children under age five, both globally and within specific countries. The result, which is the first-ever available at the country level, is expected to serve as a clarion call to developing countries to invest in pneumonia prevention programmes. 
According to the study, streptococcus pneumoniae and haemophilus influenzae type b (Hib) infections take the lives of an estimated 1.2 million children under age five each year. Safe and effective vaccines exist to provide protection against both diseases. However, use of Hib vaccine has only recently expanded to low-income countries and pneumococcal vaccine is not yet included in national immunisation programmes in the developing world, where children bear the highest risk for pneumonia and where most pneumonia-related child deaths occur. 
On streptococcus pneumoniae (pneumococcal disease), data from the study show that in 2000, there were an estimated 14.5 million cases of pneumococcal disease worldwide, and 826,000 children under five years of age died of the disease. Of the 14.5 million pneumococcal cases, 95percent were attributable to pneumonia. While the majority of pneumococcal cases (51 percent) were found in Asia due to the high population, an estimated 54 percent of pneumococcal deaths occurred in Africa, where the lack of vaccines, a high prevalence of HIV infection and lack of access to medical care contributed to the death toll.  
“Our findings underscore the urgent need for prevention efforts throughout the developing world,” said Kate O’Brien, primary author of the pneumococcal study and associate professor of International Health at the Johns Hopkins Bloomberg School of Public Health. “The need for vaccination and improved treatment is particularly urgent in Africa and Asia, which together account for 95 percent of all pneumococcal deaths,” noted. 
The 10 countries with the greatest number and greatest proportion of global pneumococcal cases were in Asia and Africa, and taken together account for 66 percent of cases worldwide. These countries include India (27 percent), China (12 percent), Nigeria (five percent), Pakistan (five percent), Bangladesh (four percent), Indonesia (three percent), Ethiopia (three percent), Democratic Republic of the Congo (three percent), Kenya (three percent) and the Philippines (percent).  
“Pneumococcal disease takes the lives of more than 85,000 Nigerian children every year – that is one child every six minutes. Just one of our children dying of a preventable disease is one too many, particularly when affordable solutions are now available to our country through the GAVI Alliance,” said Adegoke Falade, professor of pediatrics at the College of Medicine, University of Ibadan, and honorary consultant pediatrician, University College Hospital in Ibadan, Nigeria. 
“In areas of the world where access to quality care is limited, the use of pneumococcal vaccine is particularly necessary to limit disease and save lives,” said Thomas Cherian, Coordinator of the WHO Expanded Programme on Immunisation. “Implementing pneumococcal vaccine is critical if developing countries are to achieve United Nations Millennium Development Goal 4 for child mortality reduction.” 
In 2000, only the USA had initiated routine use of pneumococcal vaccine. By August 2008, it was expanded to include 24 high and two upper-middle income countries but did not include any from Africa or Asia, the regions with the highest number of pneumococcal deaths and cases. According to the study, these 26 countries accounted for less than 0.2 percent of global childhood pneumococcal deaths in 2000 and the children in these countries, on average, had a 40-fold lower risk of pneumococcal death than the children in countries not yet using the vaccine. 
Through the GAVI Alliance low income countries can access existing and future pneumococcal vaccines with only a small self-financed contribution of as little as US $0.15 per dose. By February 2009, 11 countries had received GAVI Alliance approval for support to introduce pneumococcal conjugate vaccine (PCV), including 8 in Africa and Asia. Two of these, Rwanda and the Gambia, have now initiated the use of PCV in their routine infant immunization schedules.  
“If fully rolled out in GAVI-eligible countries, the pneumococcal vaccine could save the lives of more than 440,000 children by 2015,” said Julian Lob-Levyt, CEO of the GAVI Alliance. “We encourage all developing countries to apply for this support as an important first step to saving children’s lives.” 
For Haemophilus influenzae type b (Hib) on the other hand, findings from the Hib study indicate that in 2000, Hib caused approximately 8.1 million serious illnesses worldwide and caused 371,000 child deaths. As with pneumococcal disease, the greatest burden of Hib disease lies in Asia and Africa. The 10 countries with the highest estimated number of Hib deaths in 2000 include India (72,000), Nigeria (34,000), Ethiopia (24,000), Democratic Republic of the Congo (22,000), China (19,000), Afghanistan (14,000), Pakistan (13,000), Bangladesh (12,000), Angola (9,000) and Niger (8,000). 
The World Health Organisation and the GAVI Alliance, which is supporting the Hib Initiative, have been working to expand supplies of Hib vaccine, reduce vaccine cost and assist countries with vaccine introduction. There is substantial regional variability in vaccine use, and the study suggests that expanded use of Hib vaccines could have considerable benefit in reducing child mortality worldwide.  
“Prevention of pneumococcal and Hib cases and deaths is imminently achievable, but countries must demonstrate the political will to prioritise prevention,” said Orin Levine, Executive Director of PneumoADIP at the Johns Hopkins Bloomberg School of Public Health. “Together with financial assistance now available through the GAVI Alliance, these findings give countries the information they need and should now provide a mandate for local and regional policymakers to prioritise investment in pneumonia prevention.”